Complete the form to be sure you don’t miss important updates, survey results, and other information.

Personal information

*First Name

Please fill out this field

Phone Number

Please enter a valid phone number

*Last Name

Please fill out this field

ZIP Code

Please enter a valid 5-digit ZIP code number

*Email Address

Please enter a valid email address

NPI#

Please enter a valid 10-digit NPI number

*Required fields.

I agree to the statements below and have read and accept the Legal Notice and Privacy Notice.

I authorize Teva Pharmaceuticals USA, Inc. (“Teva”), its affiliates and companies working with Teva to contact me by direct mail, email, telephone, and electronic message (including autodialed and prerecorded calls and messages) for marketing purposes, such as to provide me with information, offers and promotions regarding schizophrenia, Teva products, and programs, to conduct market research or surveys, and to use my information to develop future products, services and programs.

I understand that I may choose to no longer receive further communication from Teva by following the unsubscribe instructions on the communication.

Please read and agree to all terms and conditions

Please confirm you are not a robot

For nearly 30 years, healthcare providers have relied on
olanzapine for the treatment of schizophrenia.²

DID YOU KNOW?

Olanzapine is the most commonly prescribed oral atypical antipsychotic for schizophrenia in the outpatient setting^1*†

Olanzapine has the highest utilization among all atypical antipsychotics in the hospital setting^1*†

^*TRx data sourced from IQVIA NPA October 2025; orals factored for SCZ using Analytics Link 2022.

^†Source: IQVIA NSP; MAT March 2025; not factored for any indications.

^‡Survey on Olanzapine Needs and Attitudes Research.

THE SONAR survey ASSESSED PSYCHIATRIC CLINICIAN PERCEPTIONS OF OLANZAPINE

Data from 437 US psychiatric clinicians captured attitudes toward olanzapine.

In key clinical scenarios¹:

74%

were more likely or as likely to consider olanzapine for acute exacerbation

62%

consider olanzapine in first-episode schizophrenia

61%

consider olanzapine for suboptimal response to initial treatment

Overall, clinicians perceive olanzapine as an option in treating all stages of schizophrenia, with known associated weight-related and metabolic risks.¹

PRESCRIPTION LEADER IN THE TREATMENT OF SCHIZOPHRENIA

OLANZAPINE LEADS THE ORAL ATYPICAL CLASS¹

Man in a blue shirt looking up, smiling — Not an actual patient.

ACROSS INPATIENT AND OUTPATIENT SETTINGS

OLANZAPINE IS THE

#1prescribed oral atypical antipsychotic for schizophrenia¹*

OLANZAPINE ACCOUNTS FOR

19 %OF ALL atypical antipsychotic prescriptions¹*

IN NONFEDERAL HOSPITALS

OLANZAPINE ACCOUNTS FOR

52 % OF ALL atypical antipsychotic utilization^1†

Did you know?

IN NONFEDERAL HOSPITALS

Olanzapine>8most utilized molecules combined

Olanzapine use is greater than the next 8 most utilized molecules combined.^1†

The second most frequently prescribed atypical antipsychotic after olanzapine accounts for just 13% of nonfederal hospital utilization.^1†

*TRx data sourced from IQVIA NPA October 2025; orals factored for SCZ using Analytics Link 2022.

^†Source: IQVIA NSP; MAT March 2025; not factored for any indications.

Group of people smiling and looking up — Not actual patients.

WHAT MAKES olanzapine DISTINCT?

Select each box to the rightbelow to find out how olanzapine is intentionally designed and extensively studied in schizophrenia.⁵

Clozapine Analogue^4,5§

30 Years of Experience²

50
Studies³

>9400 Patients³

Clozapine Analogue

Olanzapine is a chemical analogue of clozapine with no requirement for routine hematologic monitoring.^4,5§

30 Years of Clinical Experience

Olanzapine is indicated and used for the acute and ongoing control of schizophrenia symptoms.²

50 Studies

Since its FDA approval in 1996, at least 50 studies have evaluated the efficacy of olanzapine.^2,3

>9400 Patients

In clinical studies, the efficacy of olanzapine has been evaluated in 9476 patients.³

Not actual patients.

^§Because leukopenia and neutropenia have been reported with antipsychotics including olanzapine, patients with a history of clinically significant low white blood cell (WBC) count or drug-induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy. Discontinuation of olanzapine should be considered at the first sign of a clinically significant decline in WBC count in the absence of other causative factors. Agranulocytosis has also been reported with antipsychotic agents. ²

Woman in a pink shirt looking up, smiling — Not an actual patient.

Did you know?

Olanzapine is on the World Health Organization's Model List of Essential Medicines.⁶

Olanzapine was approved for medical use in the United States in 1996 and was added to the World Health Organization’s List of Essential Medicines in 2023.^2,6

SHARE YOUR EXPERIENCE

TELL US HOW YOU USE OLANZAPINE IN
REAL PRACTICE

For what percentage of your adult patients with schizophrenia do you prescribe olanzapine?

Select one.

<20% 20%-50% >50%

Where does olanzapine typically fit into your treatment approach?

Select one.

First-line Second- or third-line Fourth-line or further

Rank the following patient characteristics from least to most important when determining if someone is a candidate for treatment with olanzapine.

Rank all.

Why do you think olanzapine is the #1 prescribed oral atypical antipsychotic?

Check all that apply.

Long-term efficacy Short-term efficacy Analogue to clozapine Accessibility of treatment

Fill out the form below to submit.

*Required field.

*First Name

Please fill out this field

*Last Name

Please fill out this field

*Email Address

Please enter a valid email address

I agree to the statements below and have read and accept the Legal Notice and Privacy Notice

I authorize Teva Pharmaceuticals USA, Inc. (“Teva”), its affiliates, and companies working with Teva to contact me by direct mail, email, telephone, and electronic message (including autodialed and prerecorded calls and messages) for marketing purposes, such as to provide me with information, offers, and promotions regarding Huntington’s disease, Teva products, and programs, to conduct market research or surveys, and to use my information to develop future products, services, and programs.

I understand that I may choose to no longer receive further communications from Teva by following the unsubscribe instructions on the communication.

Please read and agree to all terms and conditions

THANK YOU

We appreciate your insight. Sign up to receive results from the survey and other important information.

Question 1/4

Group of people smiling and looking up, centered on a man in a yellow shirt and a woman in a striped shirt — Not actual patients.

SIGN UP FOR UPDATES

THERE’S MORE TO DISCOVER ABOUT OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

Complete the form to be sure you don’t miss important updates, survey results, and other information.

*Required fields.

Personal information

*First Name

Please fill out this field

Phone Number

Please enter a valid phone number

*Last Name

Please fill out this field

ZIP Code

Please enter a valid 5-digit ZIP code number

*Email Address

Please enter a valid email address

NPI#

Please enter a valid 10-digit NPI number

I agree to the statements below and have read and accept the Legal Notice and Privacy Notice.

I understand that I may choose to no longer receive further communication from Teva by following the unsubscribe instructions on the communication.

Please read and agree to all terms and conditions

Please confirm you are not a robot

People shown on this website are AI-generated and not actual patients.

References: 1. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc. 2. Olanzapine orally disintegrating tablets. Prescribing information. Parsippany, NJ: Teva Pharmaceuticals USA, Inc. 3. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654. 4. Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019;15:2559-2569. 5. Kolli P, Kelley G, Rosales M, Faden J, Serdenes R. Olanzapine pharmacokinetics: a clinical review of current insights and remaining questions. Pharmgenomics Pers Med. 2023;16:1097-1108. 6. World Health Organization. WHO Model List of Essential Medicines - 24th list, 2025. Accessed October 10, 2025. https://www.who.int/publications/i/item/B09474

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. OLANZAPINE is not approved for the treatment of patients with dementia-related psychosis.

Cerebrovascular Adverse Reactions: In trials of elderly patients with dementia-related psychosis, there was a significantly higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, in patients treated with olanzapine compared to placebo. OLANZAPINE is not approved for the treatment of dementia-related psychosis.
Suicide: The possibility of a suicide attempt is inherent in schizophrenia, and close supervision of high-risk patients should accompany drug therapy.
Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status including delirium, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If NMS is suspected, immediately discontinue OLANZAPINE and provide symptomatic treatment and monitoring.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): DRESS has been reported with exposure to olanzapine. DRESS may present with a cutaneous reaction, eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. DRESS is sometimes fatal. Discontinue if DRESS is suspected.
Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes including hyperglycemia, dyslipidemia, and weight gain. Metabolic changes may be associated with increased cardiovascular/cerebrovascular risk. Olanzapine’s specific metabolic profile is presented below.
Hyperglycemia and Diabetes Mellitus (DM), in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, have been reported in patients treated with atypical antipsychotics, including olanzapine. While relative risk estimates are inconsistent, the association between atypical antipsychotics and increase in glucose levels appears to fall on a continuum, and olanzapine appears to have a greater association compared with some other atypical antipsychotics. Physicians should consider the risks and benefits when prescribing OLANZAPINE to patients with an established diagnosis of DM or with a borderline increase in blood glucose levels. Patients taking OLANZAPINE should be monitored regularly for worsening of glucose control. Patients starting treatment with OLANZAPINE should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of OLANZAPINE.
Dyslipidemia: Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using OLANZAPINE, is recommended. Clinically significant, and sometimes very high (≥500 mg/dL), elevations in triglyceride levels have been observed with olanzapine use.
Weight Gain: Potential consequences of weight gain should be considered prior to starting OLANZAPINE. Patients receiving OLANZAPINE should receive regular monitoring of weight.
Tardive Dyskinesia (TD): As with all antipsychotic medications, prescribing should be consistent with the need to minimize the risk of TD. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.
Orthostatic Hypotension and Syncope: OLANZAPINE may induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia, and in some patients, syncope, especially during the initial dose-titration period with oral OLANZAPINE. OLANZAPINE should be used with particular caution in patients with known cardiovascular disease, with cerebrovascular disease, or who are predisposed to hypotension.
Falls: OLANZAPINE may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.
Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics, including olanzapine. Patients with a history of a clinically significant low white blood cell (WBC) count or drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of OLANZAPINE should be considered at the first sign of a clinically significant decline in WBCs in the absence of other causative factors. Patients with severe neutropenia (absolute neutrophil count <1000 mm³) should discontinue OLANZAPINE and have their WBC counts checked until recovery.
Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Antipsychotic drugs, including OLANZAPINE, should be used cautiously in patients at risk for aspiration.
Seizures: OLANZAPINE should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer’s dementia. OLANZAPINE is not approved for the treatment of patients with Alzheimer disease.
Potential for Cognitive and Motor Impairment: OLANZAPINE has the potential to impair judgment, thinking, and motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that OLANZAPINE therapy does not affect them adversely.
Body Temperature Dysregulation may occur with antipsychotic agents. Appropriate care is advised when prescribing OLANZAPINE for patients who will be experiencing conditions that may contribute to elevation in core body temperature (e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, being subject to dehydration).
Anticholinergic Effects: Olanzapine exhibits in vitro muscarinic receptor affinity. In premarketing clinical trials, olanzapine was associated with constipation, dry mouth, and tachycardia, all adverse reactions possibly related to cholinergic antagonism. OLANZAPINE should be used with caution in patients with a current diagnosis or prior history of urinary retention, clinically significant prostatic hypertrophy, constipation, or a history of paralytic ileus or related conditions. In postmarketing experience, the risk for severe adverse reactions (including fatalities) was increased with concomitant use of anticholinergic medications.
Hyperprolactinemia: As with other drugs that antagonize dopamine receptors, OLANZAPINE elevates prolactin levels, and the elevation persists during administration. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

The most common treatment-emergent adverse events (incidence of ≥5% and greater than placebo) associated with oral olanzapine (vs placebo) in 6-week schizophrenia trials in adults were somnolence (26% vs 15%), dizziness (11% vs 4%), weight gain (6% vs 1%), personality disorder (COSTART term for nonaggressive objectional behavior; 8% vs 4%), constipation (9% vs 3%), akathisia (5% vs 1%), and postural hypotension (5% vs 2%).

The most common treatment-emergent adverse events (incidence of ≥5% and greater than placebo) associated with oral olanzapine (vs placebo) in 3- and 4-week bipolar I disorder (manic or mixed episodes) trials in adults were somnolence (35% vs 13%), dry mouth (22% vs 7%), dizziness (18% vs 6%), asthenia (15% vs 6%), constipation (11% vs 5%), dyspepsia (11% vs 5%), increased appetite (6% vs 3%), and tremor (6% vs 3%).

The most common treatment-emergent adverse events (incidence of ≥5% and greater than placebo) associated with oral olanzapine (vs placebo) in clinical trials of adolescents (aged 13-17 years) were sedation (44% vs 9%), weight increased (30% vs 6%), increased appetite (24% vs 6%), headache (17% vs 12%), fatigue (9% vs 4%), liver enzymes increased (8% vs 1%), dizziness (7% vs 2%), dry mouth (6% vs 0%), and pain in extremity (5% vs 1%).

Diazepam: may potentiate orthostatic hypotension
Alcohol: may potentiate orthostatic hypotension
Carbamazepine: increased clearance of olanzapine
Fluvoxamine: may increase olanzapine levels
Olanzapine and fluoxetine in combination: also refer to the Drug Interactions section of the package insert for Symbyax
CNS acting drugs: caution should be used when used in combination with other centrally acting drugs and alcohol
Antihypertensive agents: enhanced antihypertensive effect
Levodopa and dopamine agonists: may antagonize levodopa/dopamine agonists
Other concomitant drug therapy: when using olanzapine in combination with lithium or valproate, refer to the Drug Interactions sections of the package insert for those products

Pregnancy: Use only if potential benefit justifies the potential risk to the fetus. May cause extrapyramidal symptoms (EPS) and/or withdrawal symptoms in neonates with third-trimester exposure. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including OLANZAPINE, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or online at http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/
Lactation: OLANZAPINE is present in human milk. Infants should be monitored for excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors and abnormal muscle movements).
Fertility: OLANZAPINE may cause a reversible reduction in fertility in females.
Pediatric Use: Oral olanzapine is indicated for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13 to 17 years. The recommended starting dose for adolescents is lower than that for adults. Compared with patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin, and hepatic transaminase levels. When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential for weight gain and hyperlipidemia compared with adults. Clinicians should consider the long-term risks when prescribing to adolescents, and in many cases, this may lead them to consider prescribing other drugs first in adolescents. Medication treatment for adolescent schizophrenia and bipolar I disorder should be initiated only after a thorough diagnostic evaluation and careful consideration of the risks associated with medication treatment. Medication treatment for both adolescent schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational, and social interventions. Safety and effectiveness of olanzapine in patients younger than 13 years have not been established.

OLANZAPINE Orally Disintegrating Tablets are indicated for the treatment of schizophrenia, for acute manic and mixed episodes of bipolar I disorder, and for maintenance treatment in bipolar I disorder.

Please see the full Prescribing Information for OLANZAPINE, including Boxed WARNING.

Personal information

PRESCRIPTION LEADER IN THE TREATMENT OF SCHIZOPHRENIA

OLANZAPINE LEADS THE ORAL ATYPICAL CLASS1

ACROSS INPATIENT AND OUTPATIENT SETTINGS

IN NONFEDERAL HOSPITALS

Did you know?

WELL-ESTABLISHED MOLECULE

WHAT MAKES olanzapine DISTINCT?

Did you know?

SHARE YOUR EXPERIENCE

TELL US HOW YOU USE OLANZAPINE IN REAL PRACTICE

THANK YOU

SIGN UP FOR UPDATES

THERE’S MORE TO DISCOVER ABOUT OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

Personal information

You are about to leave this site

OLANZAPINE LEADS THE ORAL ATYPICAL CLASS¹

TELL US HOW YOU USE OLANZAPINE IN
REAL PRACTICE